New Jersey is currently home to 1653 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Brunswick, Hackensack, Newark and Morristown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Iscador® P (Mistletoe) Immunotherapy for Recurrent Osteogenic Sarcoma
NCT05726383
Recruiting
This will be a phase II, single arm study of osteosarcoma patients with fully resected pulmonary metastases. The MTD corresponds to the dosage recommendations of the manufacturer of Iscador® P which is licensed in Sweden, New Zealand, South Korea, Germany and Switzerland for the treatment of solid tumors and precancerous lesions. The study population includes patients with relapse of osteosarcoma in the lung following surgical resection of all gross disease (2nd or greater CR). Following comple... Read More
Gender:
ALL
Ages:
Between 8 years and 30 years
Trial Updated:
11/13/2024
Locations: Hackensack University Medical Center, Hackensack, New Jersey
Conditions: Osteogenic Sarcoma Recurrent
Register for Updates
ETMR One: An International Registry and Research Platform for Children With Embryonal Tumor With Multilayer Rosettes
NCT04794686
Recruiting
This research is being done to find out more information about a brain tumor called Embryonal Tumor with Multilayer Rosettes (ETMR) by collecting medical information from children who have this disease. The purpose of this research study is to create and maintain a research database for patients with ETMR. The database will include information about occurrence rates, patient information, tumor tissue information, and response to treatment. This will help advance our understanding of this rare d... Read More
Gender:
ALL
Ages:
All
Trial Updated:
11/13/2024
Locations: Hackensack University Medical Center, Hackensack, New Jersey
Conditions: Embryonal Tumor With Multilayered Rosettes
Register for Updates
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
NCT02628067
Recruiting
In this study, participants with multiple types of advanced (unresectable and/or metastatic) solid tumors who have progressed on standard of care therapy will be treated with pembrolizumab (MK-3475).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/13/2024
Locations: Call for Information (Investigational Site 0008), New Brunswick, New Jersey
Conditions: Advanced Cancer, Anal Carcinoma, Anal Cancer, Biliary Cancer, Cholangiocarcinoma, Bile Duct Cancer, Neuroendocrine Tumor, Carcinoid Tumor, Endometrial Carcinoma, Endometrial Cancer, Cervical Carcinoma, Cervical Cancer, Vulvar Carcinoma, Vulvar Cancer, Small Cell Lung Carcinoma, Small Cell Lung Cancer (SCLC), Mesothelioma, Thyroid Carcinoma, Thyroid Cancer, Salivary Gland Carcinoma, Salivary Gland Cancer, Salivary Cancer, Parotid Gland Cancer, Advanced Solid Tumors, Colorectal Carcinoma
Register for Updates
Internet Assisted Career-Oriented Soft-skills Training for Transition Age Youth with Mental Health Conditions
NCT05766280
Recruiting
The purpose of this study is to evaluate the effectiveness of an internet- assisted Career-Oriented Work-Related Soft-skills Training (iCareer) intervention, infused with cognitive behavioral therapy, targeting individuals ages 16-24 with mental health conditions, to improve employment outcomes. The overall objective is to help transition-age youth (TAY) with psychiatric disabilities achieve optimal employment outcomes as part of successful transition to adulthood. Findings will have implication... Read More
Gender:
ALL
Ages:
Between 16 years and 24 years
Trial Updated:
11/12/2024
Locations: Rutgers Univeristy, Newark- Office of Disability Services, Newark, New Jersey
Conditions: Mental Health Wellness 1, Mental Health Wellness 2, Occupational Problems
Register for Updates
Identify the Optimal TMS Target to Modulate Reward Activity
NCT05766254
Recruiting
Our primary goal will be to identify the optimal prefrontal-cingulate target by systematically measuring the efficacy of various image-based targeting techniques to increase the reward positivity using the 10-Hz TMS protocol in dependent smokers. Our secondary objective will be to measure the targets' effectiveness to increase decision-making capacity using the probabilistic selection task (PST). Our third objective will be to specifically assess whether the TMS targets has a differential impact... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
11/12/2024
Locations: Rutgers University - Newark, Newark, New Jersey
Conditions: Nicotine Use Disorder
Register for Updates
Characterization of the Temporo-masseteric Nerve Block (TMNB) in Healthy Subjects
NCT05507164
Recruiting
The proposed pilot study is aimed at preliminary characterization of the TMNB injection in 20 healthy volunteers. Assessment of bite-force distribution and surface electromyographic activity of the temporalis and the masseter muscles, at rest and clench, before and after unilateral TMNB injection, will be the primary outcome measures. Post-injection assessments will be performed at 30 minutes, 2 hours, and 2 weeks after the injection. Participants will be surveyed regarding their experience rece... Read More
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
11/12/2024
Locations: Rutgers School of Dental Medicine, Newark, New Jersey
Conditions: Occlusion
Register for Updates
Empathic Communication Skills (ECS) Training
NCT05456841
Recruiting
Research indicates that perceived stigma within medical encounters is prevalent and problematic for lung cancer patients' well-being and quality of cancer care. Promoting empathic communication appears to be a potentially effective intervention target to help reduce patients' perceptions of stigma within clinical encounters; however, no formal trainings exist that focus on teaching empathic communication to oncology care providers (OCPs). Building upon favorable findings from a prior R21 (R21CA2... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
11/12/2024
Locations: Hackensack Meridian Health (Data collection only), Hackensack, New Jersey
Conditions: Lung Cancer
Register for Updates
Microbiome Derived Metabolism and Pharmacokinetics
NCT05065671
Recruiting
The investigators will perform single-dose pharmacokinetic (PK) studies in humans following administration of drugs with known microbiome derived metabolism (MDM) in parallel with preclinical studies. By directly comparing laboratory measurements to clinical results, the investigators will be able to confirm the relevance of MDM in vivo, create microbiome-dependent PK profiles of the MDM positive drugs, and establish methodology to capture the contribution of MDM to inter-individual variability... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
11/12/2024
Locations: Robert Wood Johnson University Hospital Somerset, Somerville, New Jersey
Conditions: Microbial Colonization
Register for Updates
Immunoglobulin G Therapy Dose Optimization
NCT04818177
Recruiting
The overall goal of this proposal is to investigate effects of obesity on pharmacokinetics of immunoglobulin G (IgG) and to develop strategies for optimization of dosing of IgG in obese patients. There is an ongoing debate regarding the most appropriate dosing of IgG formulations in obese patients. Obesity poses significant health risks; and evidence supporting dosing strategies of IgG in obese patients is inadequate. Some of the adverse reactions have been attributed to a relative overdosing in... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
11/12/2024
Locations: Robert Wood Johnson University Hospital Somerset, Somerville, New Jersey
Conditions: Obesity, Immune Deficiency
Register for Updates
A Study of Sotorasib in People with Non-Small Cell Lung Cancer
NCT06582771
Recruiting
The researchers are doing this study to see if sotorasib is a safe and effective treatment for people with advanced non-small cell lung cancer (NSCLC) with a KRAS G12C mutation who have not received treatment for their cancer since it became advanced. (Participants have not received a "first-line therapy" since their cancer became advanced.)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/11/2024
Locations: Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey
Conditions: Non Small Lung Cancer
Register for Updates
Phase 2 Study of AFM13 in Combination with AB-101 in Subjects with R/R HL and CD30+ PTCL
NCT05883449
Recruiting
AFM13-203 is a phase 2, open-label, multi-center, multi-cohort study with a safety run-in followed by expansion cohorts. The study is evaluating the safety and efficacy of AFM13 in combination with AB-101 in subjects with R/R classical HL and CD30-positive PTCL.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/11/2024
Locations: John Theurer Cancer Center, Hackensack, New Jersey
Conditions: Relapsed or Refractory Hodgkin Lymphoma, Peripheral T Cell Lymphoma
Register for Updates
Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm
NCT04317534
Recruiting
A randomized trial of adjuvant Pembrolizumab following surgical resection versus observation following surgical resection in patients with stage I non-small cell lung cancer (NSCLC) with primary tumors between 1-4 cm. Patients will be randomized (1:1) 4-12 weeks following surgery to either: * Arm A: Pembrolizumab 400 mg every 6 weeks × 9 cycles * Arm B: Observation Stratification factors will include: PD-L1 TPS (\<50% vs. ≥50%), and tumor size (1-2 cm vs. \>2-4 cm)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/11/2024
Locations: Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey
Conditions: NSCLC, Stage I
Register for Updates